Odyssean LLC Buys New Shares in ADMA Biologics Inc $ADMA

Odyssean LLC bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 124,498 shares of the biotechnology company’s stock, valued at approximately $1,042,000. Odyssean LLC owned 0.06% of ADMA Biologics at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Lido Advisors LLC increased its stake in shares of ADMA Biologics by 3.8% during the 4th quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company’s stock valued at $312,000 after acquiring an additional 629 shares during the last quarter. Cim LLC lifted its holdings in shares of ADMA Biologics by 0.7% during the 3rd quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock worth $1,341,000 after acquiring an additional 665 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of ADMA Biologics by 28.9% in the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 700 shares during the last quarter. Cerity Partners LLC boosted its position in shares of ADMA Biologics by 1.8% in the second quarter. Cerity Partners LLC now owns 48,572 shares of the biotechnology company’s stock worth $884,000 after acquiring an additional 869 shares during the last quarter. Finally, Legato Capital Management LLC grew its holdings in ADMA Biologics by 4.7% in the fourth quarter. Legato Capital Management LLC now owns 30,895 shares of the biotechnology company’s stock valued at $564,000 after purchasing an additional 1,374 shares during the period. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Stock Up 0.4%

Shares of NASDAQ:ADMA opened at $9.62 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.81 and a current ratio of 6.97. ADMA Biologics Inc has a 1 year low of $7.21 and a 1 year high of $20.46. The stock has a market capitalization of $2.15 billion, a P/E ratio of 13.74 and a beta of 0.78. The stock has a 50-day simple moving average of $9.15 and a 200-day simple moving average of $10.31.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. The firm had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. ADMA Biologics’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.14 earnings per share. Equities analysts forecast that ADMA Biologics Inc will post 0.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Zacks Research upgraded shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday. Raymond James Financial assumed coverage on shares of ADMA Biologics in a research note on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price objective for the company. Finally, Mizuho dropped their price objective on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $18.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.